SITC Updates

Oncology News Burst from the FDA: FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma

By SITC Communications posted 5 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

SITC Hosts "Non-invasive Biomarkers for irAEs: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 13 days ago
On June 18, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the fourth computational immuno-oncology webinar of series 5. The webinar was structured in three parts: (1) An overview of the current landscape of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy; (2) a review of the progress made to date in identifying and defining biomarkers for irAEs; (3) a presentation by Dr. Villani on methodologies developed in her laboratory at Massachusetts General Hospital aimed at identifying non-invasive biomarkers of irAEs. The session concluded with a discussion of ...

Immune Monitor - June 2025

By SITC Communications posted 14 days ago
A Message from the President Every June, we honor Cancer Immunotherapy Month, an opportunity to highlight advancements, acknowledge future potential and celebrate the individuals driving innovation in cancer immunotherapy. While we celebrate the paradigm shift in cancer care our community pioneered, we still have much to do. The SITC leadership is committed to driving the science of biomarker discovery, optimizing patient selection in early phase clinical trials so that the right patient finds the right immunotherapy at the right time. Most recently, SITC published a commentary in the Journal for ImmunoTherapy of Cancer ( JITC ), “ A SITC Perspective: ...

JITC Digest June 2025

By JITC Publications posted 20 days ago
INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | Updated Journal Metrics | Popular Archive Articles Letter from the Editor Hello JITC Readers, With the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting behind us, we can now look forward to getting our abstracts for the SITC meeting in the fall with the submission deadline coming up on June 26 th ! The ASCO meeting, for me, was a wonderful time at the SITC booth to catch up with old friends from around the world, SITC staffers, and biotech and pharma companies working hard along ...

Oncology News Burst from the FDA: FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

By SITC Communications posted 25 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

SITC Hosts "Lessons from the CIMAC-CIDC Network: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 06-04-2025
The focus of this webinar on May 29th, 2025 was exploring how machine learning-driven modeling of multimodal data can be used to profile patient heterogeneity and analyze diverse immunotherapy treatments, enabling the identification of cellular and molecular markers linked to clinical outcomes. View the webinar for FREE on-demand HERE .

Highlights from ASCO June 3, 2025

By Thomas Martin posted 06-04-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on June 3, 2025. 2025 Scientific Highlights Subgroup analyses of COMPASSION-16: Bispecific PD-1 x CTLA-4 antibody cadonilimab plus chemotherapy with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer 5509. Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16. Xiaohua Wu (Fudan University Shanghai Cancer Center, Shanghai, China) ...

Highlights from ASCO June 2, 2025

By Thomas Martin posted 06-03-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on June 2, 2025. 2025 Scientific Highlights Dose finding and dose expansion reports of LINKER-MM2, linvoseltiamab, a BCMAxCD3 bispecific antibody, in combination with protease inhibitor bortezomib for patients with heavily pretreated multiple myeloma 7510. Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial. Xavier Leleu (Hospital La Mileterie, Poitiers, France) presented ...

Highlights from ASCO June 1, 2025

By Thomas Martin posted 06-02-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on June 1, 2025. 2025 Scientific Highlights Making “cold” colorectal cancer tumors “hot”: A novel first-in-class PD-1/IL-2 bispecific antibody fusion protein for patients with advanced colorectal cancer 104. Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer. Zhenyu Lin (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China ) presented pooled analyses ...

Highlights from ASCO May 31, 2025

By Thomas Martin posted 06-01-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on May 31, 2025. 2025 Scientific Highlights Adjuvant cemiplmab prevents recurrence of cutaneous squamous cell carcinoma in patients at high risk of disease recurrence 6001. Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). Danny Rischin (Peter MacCallum Cancer Centre, Melbourne, VIC, Australia) presented the primary analysis of the phase 3 C-POST study comparing the efficacy and safety of adjuvant ...

Highlights from ASCO May 30, 2025

By Thomas Martin posted 05-31-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on May 30, 2025. 2025 Scientific Highlights Continued clinical benefits of nivolumab and ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer 3501. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW. Heniz-Josef Lenz (University of Southern California ...

Gastrointestinal Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 05-30-2025
An update to "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer,” published in Journal for ImmunoTherapy of Cancer ( JITC ), is now available. In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and ...

Gastrointestinal Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 05-30-2025
An update to "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer,” published in Journal for ImmunoTherapy of Cancer ( JITC ), is now available. In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and ...

Immune Monitor - May 2025

By SITC Communications posted 05-27-2025
A Message from the President Since SITC’s founding in 1985, the society has proudly supported the immuno-oncology (IO) community as the field has grown into a transformative standard of care for many cancer patients. As we celebrate our 40 th anniversary, we are thrilled to return to the Gaylord National Harbor Resort & Convention Center in National Harbor, MD, for the 40 th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025) , taking place Nov. 5–9. This gathering will be a chance to reflect on the extraordinary progress our community has achieved over the past four decades, while also looking to the promising future of cancer ...

JITC Digest May 2025

By SITC Communications posted 05-27-2025
INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | JITC Meet-the-Editor Session at ASCO 2025 Popular Archive Articles Letter from the Editor Hello JITC Readers, This month, I attended the American Association of Immunology (AAI) Conference and was invigorated by the quality of the science and the substantial unpublished data that was presented. There was sufficient tumor immunology presented, including a SITC-sponsored session on cell therapy for cancer, to keep me fully engaged. Major advances in the intersection of immunobiology not only with ...

Oncology News Burst from the FDA: FDA Approves Retifanlimab-dlwr With Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

By SITC Communications posted 05-16-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

SITC Hosts "Guidelines and Best Practices on Designing Clinical Trials with Exploratory Surrogate Endpoints and CDX: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 05-15-2025
This webinar on May 8th discussed how exploratory surrogate endpoints and companion diagnostics (CDX) are transforming clinical trial design in immuno-oncology, crucial for advancing personalized medicine. By incorporating these innovative approaches, researchers can gain early insights into treatment efficacy, enhancing the likelihood of successful drug approval. Join us to explore how these guidelines and best practices can shape the future of clinical trials and drive progress in immunotherapy. View the webinar for FREE on-demand HERE.

SITC Publishes Third Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy

By SITC Scientific Publications News posted 05-14-2025
SITC is pleased to announce the publication of a new manuscript titled “A SITC Strategic Vision: Prevention, Premalignant Immunity, Host and Environmental Factors,” available now in the Journal for ImmunoTherapy of Cancer ( JITC ). This manuscript is the third in a JITC Special Series — The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer, which outlines the current state of the field, elevates the most pressing challenges, and proposes the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. This series will serve as an update to the ...

SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual Meeting

By Thomas Martin posted 05-13-2025
SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual Meeting Celebrating 40 years of driving breakthroughs in cancer immunotherapy MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Jennifer A. Wargo, MD, MMSc, from The University of Texas MD Anderson Cancer Center as the Keynote Speaker at its 40 th Anniversary Annual Meeting and Pre-Conference Programs (SITC 2025) with her presentation “Targeting the Microbiome to Promote Health and End Cancer.” SITC also hosts Ira Mellman, PhD, FAACR, FAIO from the Parker Institute for Cancer Immunotherapy and ...

NEW! SITC 40th Anniversary: I-O Progress and Potential

By JITC Publications posted 05-02-2025
In celebration of the 40 th Anniversary of the Society for Immunotherapy of Cancer (SITC), the Journal for ImmunoTherapy of Cancer ( JITC ) presents this special series of commentaries from luminaries in the field of immuno-oncology. Numerous SITC Fellows of the Academy of Immuno-Oncology and Richard V. Smalley Memorial Award recipients put pen to paper to provide their insights into current achievements in various areas of the field while also sharing their personal, forward-looking vision of where the field is moving in the upcoming decades. As SITC looks forward with anticipation of exciting new developments, JITC aims to deepen the science of cancer ...